# Metabolic Signatures and Biomarkers in Schizophrenia

> **NCT00466310** · PHASE1 · COMPLETED · sponsor: **Duke University** · enrollment: 71 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Risperidone
- **OTHER:** Healthy volunteers

## Key facts

- **NCT ID:** NCT00466310
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-01
- **Final completion:** 2011-01
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2014-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466310, "Metabolic Signatures and Biomarkers in Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00466310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*